Putting the efficacy of psychiatric and general medicine medication into perspective: review of meta-analyses

Cited by (450)

Items 201–300 of 450

1. What factors indicate prognosis for adults with depression in primary care? A protocol for meta-analyses of individual patient data using the Dep-GP database
   Joshua E. J. Buckman, Rob Saunders, Zachary Daniel Cohen, Katherine Clarke, Gareth Ambler, Robert J. DeRubeis, Simon M. Gilbody, Steven D. Hollon, Tony Kendrick, Edward R. Watkins et al. · 2019 · Wellcome Open Research
2. Cyberbully victimization and its association with residual depressive symptoms among clinically stable adolescents with psychiatric disorders during the COVID-19 pandemic: A perspective from network analysis
   Xiaomeng Xie, Hong Xin Cai, Shu-Ying Li, Zong-Lei Li, Wuyang Zhang, Yan-Jie Zhao, Yao Zhang, Gabor Sandor Ungvari, Yi‐lang Tang, Fan He et al. · 2023 · Frontiers in Psychology
3. Antidepressants; what’s the beef?
   Guy M. Goodwin, David Nutt · 2019 · Acta Neuropsychiatrica
4. Zinc as an adjunct to antidepressant medication: a meta-analysis with subgroup analysis for different levels of treatment response to antidepressants
   Andreas Donig, Martin Hautzinger · 2021 · Nutritional Neuroscience
5. Antipsychotics decrease response confidence
   Steffen Moritz, Katharina Kolbeck, Christina Andreou · 2016 · Journal of Psychopharmacology
6. Defending psychiatry or defending the trivial effects of therapeutic interventions? A citation content analysis of an influential paper
   Ioana A. Cristea, Florian Naudet · 2017 · Epidemiology and Psychiatric Sciences
7. Ireland’s Mental Health Bill 2024: progress, problems and Procrustean perils
   Brendan D. Kelly · 2024 · Irish Journal of Medical Science (1971 -)
8. The Field of Schizophrenia: Strengths, Weaknesses, Opportunities, and Threats
   John Michael Kane, Barbara A. Cornblatt, Christoph Ulrich Correll, Terry E. Goldberg, Todd Lencz, Anil K. Malhotra, Delbert G. Robinson, Philip R. Szeszko · 2011 · Schizophrenia Bulletin
9. Treatment profiles in a Danish psychiatric university hospital department
   Niels Okkels, Rasmus Beyer Mogensen, Lea Catherine Crean, Claus Høstrup Vestergaard, Søren Skadhede, Camilla Rasmussen, Jan Walter Dhillon Shanmuganathan, Kenneth Brandt Hansen, Povl Munk‐Jørgensen · 2017 · Nordic Journal of Psychiatry
10. Are the effects of methylphenidate uncertain?
    Samuele Cortese · 2018 · Irish Journal of Psychological Medicine
11. Mood matters: a national survey on attitudes to depression
    John Richard Kelly, Mary Cosgrove, Cian Judd, Kathy Scott, Aoibheann Mc Loughlin, Veronica O’Keane · 2019 · Irish Journal of Medical Science (1971 -)
12. Are antidepressants clinically useful? Conclusion of a decade of debate
    Konstantinos Ν. Fountoulakis, Hans‐Jürgen Möller · 2014 · World Psychiatry
13. Self-regulation interventions – what do we know and where should we go?
    Ronan E. O’Carroll · 2019 · Health Psychology Review
14. The early intervention debate provides a distraction from another ‘unspeakable truth’
    John Joseph McGrath · 2012 · Australian & New Zealand Journal of Psychiatry
15. Health Psychology interventions
    Ronan E. O’Carroll · 2013 · British Journal of Health Psychology
16. Deprescribing antidepressants for depression – what is the evidence for and against?
    Jeffrey CL Looi, Stephen C Allison, Tarun Joseph Bastiampillai, Steve R Kisely, Paul A Maguire, Luke Sy‐Cherng Woon, Katrina Anderson, Gin Singh Malhi · 2024 · Australasian Psychiatry
17. Pharmakologische und rechtliche Grundkenntnisse der Psychopharmakotherapie
    Manfred Gerlach · 2021 · PSYCH up2date
18. A systematic review and synthesis of 489 studies investigating treatments for negative symptoms in the schizophrenia spectrum: Trial designs, demographics and clinical characteristics
    Stefano Damiani, Aldo D'Imperio, Joaquim Raduà, Lydia Fortea, Matteo Calò, Andrea Crippa, Cecilia Maria Esposito, Estella Linda Luisa Lumer, Sara Patron, Alessandro Peviani et al. · 2025 · Psychiatry Research
19. Do antipsychotics work in people with schizophrenia? A review of outcomes and effect sizes
    Christoph Ulrich Correll · 2025 · CNS Spectrums
20. Psychotropic medicine beliefs, side effects and adherence in schizophrenia: a patient–caregiver dyad perspective
    Irene Akwo Kretchy, Bernard Appiah, Kofi Agyabeng, Emmanuel Bugyei Kwarteng, Enyonam Ganyaglo, Grace Owusu Aboagye · 2021 · International Journal of Clinical Pharmacy
21. Chronic Use of Antipsychotics in Schizophrenia: Are We Asking the Right Question?
    José M. Rubio, M. Mercedes Pérez-Rodríguez · 2022 · Schizophrenia Bulletin Open
22. The biological paradigm of psychosis in crisis: A Kuhnian analysis
    Mark Pearson, Stefan Rennick‐Egglestone, Gary Winship · 2023 · Nursing Philosophy
23. Conflict and antagonism within global psychiatry: A discourse analysis of organisational responses to the UN reports on rights‐based approaches in mental health
    Jeppe Oute, Susan McPherson · 2023 · Sociology of Health & Illness
24. Placebo controls in clinical trials: concerns about use in relapse prevention studies in schizophrenia
    Robin Alexander Emsley, W. Wolfgang Fleischhacker, Silvana Galderisi, Lisa Halpern, Joseph P. McEvoy, Nina R. Schooler · 2016 · BMJ
25. Definition and Epidemiology of Treatment Resistance in Psychiatry
    Sanne Y. Smith-Apeldoorn, Jolien K. E. Veraart, Robert A. Schoevers · 2018 · Springer eBooks
26. Ripensare la pratica psichiatrica: riflessioni sul ruolo della psichiatria nella società moderna
    Federica Pinna, Valeria Del Vecchio, Mario Luciano, Gaia Sampogna, Corrado De Rosa, Sílvia Ferrari, Luca Pingani, Ilaria Tarricone, Umberto Volpe, Giuseppe Carrà et al. · 2015 · Rivista di psichiatria
27. rTMS deserves a fair chance as a novel treatment for depression
    André Aleman, Christina W. Slotema, Iris E. Sommer · 2014 · Acta Psychiatrica Scandinavica
28. Cognitive go/No-go decision-making criteria in Alzheimer’s disease drug development
    Wessels, Alette M., Edgar, Chris J., Nathan, Pradeep J., Siemers, Eric R., Maruff, Paul, Harrison, John · 2021 · Drug Discovery Today
29. Acceptance and commitment therapy among caregivers of people with cancer: a systematic review and meta-analysis
    Yunfan Gu, Mingyu Duan, Yanyan Huang, Maorong Hu, Mengjie Bao, Fang Yang · 2025 · Scientific Reports
30. Prospects for improved prevention and treatment of neuropsychiatric disorders: Neuroscience Applied
    Andreas Meyer‐Lindenberg, Suzanne L. Dickson, Mark John Millan, Gitte M. Knudsen · 2022 · Neuroscience Applied
31. Human rights in psychiatric practice: an overview for clinicians
    Brendan D. Kelly · 2015 · BJPsych Advances
32. Psychosis susceptibility syndrome: an alternative name for schizophrenia
    Iris E. Sommer, René S. Kahn · 2014 · The Lancet Psychiatry
33. Why don’t more doctors choose a career in psychiatry?
    Tanya Deb, G Alice Lomax · 2014 · BMJ
34. Psychiatry's Future: Biology, Psychology, Legislation, and “The Fierce Urgency of Now”
    Brendan D. Kelly · 2020 · Indian Journal of Psychological Medicine
35. Glyceryl trinitrate in first-episode psychosis unmedicated with antipsychotics: A randomised controlled pilot study
    Kate Merritt, Ana Catalán, Samuel Cowley, Arsime Demjaha, Matthew John Taylor, Philip K. McGuire, Ruth E Cooper, Paul Morrison · 2020 · Journal of Psychopharmacology
36. Timing of antipsychotics and benzodiazepine initiation during a first episode of psychosis impacts clinical outcomes: Electronic health record cohort study
    M. Arribas, M. Solmi, T. Thompson, D. Oliver, P. Fusar-Poli · 2022 · Frontiers in Psychiatry
37. Nebenwirkungen von Psychopharmaka: Tipps für die Praxis
    Anna Grunze, Rajnish Mago, Heinz Grunze · 2017 · DMW - Deutsche Medizinische Wochenschrift
38. Network meta-analysis of antidepressants – Authors' reply
    Andrea Cipriani, Georgia Salanti, Toshi A. Furukawa, Erick H. Turner, John P. A. Ioannidis, John Richard Geddes · 2018 · The Lancet
39. Possibly no baseline severity effect for antidepressants versus placebo but for antipsychotics. Why?
    Stefan Leucht, Stephen Z. Levine, Myrto T. Samara, Andrea Cipriani, John M. Davis, Toshi A. Furukawa · 2018 · European Archives of Psychiatry and Clinical Neuroscience
40. Small Sample Sizes and a False Economy for Psychiatric Clinical Trials
    Shitij Kapur, Marcus Robert Munafo · 2019 · JAMA Psychiatry
41. Antidepressants do work after all
    Allan Hunter Young, Calum D. Moulton · 2020 · Journal of Psychopharmacology
42. Multi-level protection of rights: India's Mental Healthcare Act, 2017 and the United Nations' Convention on the Rights of Persons with Disabilities (Articles 12 and 14)
    Brendan D. Kelly · 2023 · International Journal of Law and Psychiatry
43. Attitudes of South Australian psychiatrists towards attention deficit hyperactivity disorder in adults
    Claudia Cao, Callum Deakin, Shane Gill · 2023 · Australasian Psychiatry
44. Underused treatments in psychiatry: electroconvulsive therapy, clozapine and lithium
    Neil Mayfield, Suzy Ker, Nicola Taylor · 2025 · BJPsych Advances
45. Psychotic symptoms during pharmacological treatment of ADHD: clinical considerations and research needs.
    S. Cortese, M. Garcia-Argibay, Dominic Oliver, Zheng Chang, L. Farhat, Michael H. Bloch, G. S. de Pablo, Henrik Larsson, Marco Solmi, C. Correll et al. · 2025 · Lancet psychiatry
46. History, ‘nowtime’ ( jetztzeit ) and dialectical images: introduction to Walter Benjamin for psychiatry (I)
    George Ikkos, Giovanni Stanghellini, Alastair Morgan · 2024 · International Review of Psychiatry
47. A comparison of clinical characteristics and course predictors in early‐ and childhood‐onset schizophrenia
    Saliha Baykal, Abdullah Bozkurt, Cansu Çobanoğlu Osmanlı, Bedia Sultan Önal, Berkan Şahin, Zeynep Nur Karadoğan, Mehmet Karadağ, Zehra Hangül, Fethiye Kılıçaslan, Hamza Ayaydın et al. · 2024 · Early Intervention in Psychiatry
48. Patterns and predictors of 12-month treatment of common anxiety, mood, and substance use disorders in the World Mental Health (WMH) surveys: treatment in the context of perceived need
    Dan Joseph Stein, Daniel Vigo, Meredith Harris, Alan E. Kazdin, María Carmen Viana, Irving H. Hwang, Timothy L. Kessler, Sophie M. Manoukian, Nancy A. Sampson, Jordi Alonso et al. · 2025 · International Journal of Mental Health Systems
49. Individual-Specific Analysis for Psychoradiology
    Hesheng Liu, William J. Liu, Danhong Wang, Louisa Dahmani · 2019 · Neuroimaging Clinics of North America
50. Side-effect monitoring of continuing LAI antipsychotic medication in UK adult mental health services
    C. Paton, T. Craig, Brittany McConnell, T. Barnes · 2021 · Therapeutic Advances in Psychopharmacology
51. Depression, Angststörungen, bipolare Störung, Schizophrenie, Aufmerksamkeitsdefizithyperaktivitätssyndrom
    Johanna Seifert, Stefan Bleich, Roland Seifert · 2022 · Springer eBooks
52. Zeit in der psychodynamischen Psychotherapie
    D. Huber, G. Klug · 2015 · Psychotherapeut (Berlin)
53. Is There a Role for Antidepressant and Antipsychotic Pharmacogenetics in Clinical Practice in 2014?
    Benoit H. Mulsant, Eric J. Lenze · 2014 · The Canadian Journal of Psychiatry
54. A mindfulness- and relaxation-based nature intervention improves mood in depressed patients in psychosomatic rehabilitation: Results from the GREENCARE non-randomized controlled clinical trial
    Markus Müller, Patricia Zieris, Meike Krebs-Fehrmann, Katharina Thümer, Peter Loreth, Doris Pokorny, Florian Katzlberger, Grec Arpad, Elisabeth Kals · 2024 · Journal of Environmental Psychology
55. Wim van den Brink and colleagues reply to Des Spence and Alain Braillon
    Wim van den Brink, Karl F Mann, Antoni Gual, Henri‐Jean Aubin · 2014 · BMJ
56. Antipsychotic drugs for prevention of relapse
    Jim van Os, Oliver David Howes · 2012 · The Lancet
57. Evaluation of long acting, oral and combination antipsychotic treatments in patients with psychotic disorder (tur)
    Yasir Şafak, Süheyla Doğan Bulut, H. Karadağ, S. Örsel · 2020 · Journal of Clinical Psychiatry
58. Regional analysis of UK primary care prescribing and adult service referrals for young people with attention-deficit hyperactivity disorder: from little to very little
    Samuele Cortese · 2020 · BJPsych Open
59. From the Incomprehensible to the Partially Understood. An Update on Cognitive Bias Research and Metacognitive Training in Schizophrenia Psychosis
    Steffen Moritz, Brooke C. Schneider · 2016 · Current Treatment Options in Psychiatry
60. Choosing to UseCompared toTakingMedication: The Meaning of Medication as Described by People Who Experience Schizophrenia
    Susan Liersch-Sumskis, Lorna Jane Moxham, Janette Curtis · 2014 · Perspectives In Psychiatric Care
61. Being influential or being misleading? Citation bias in psychiatric research and practice
    Andrea Fiorillo, Mario Luciano, Gaia Sampogna · 2018 · Epidemiology and Psychiatric Sciences
62. Psychiatry is the flagship of personalized and precision medicine: proposing an epistemic horizon to biological psychiatry
    Ridha Joober · 2022 · Journal of Psychiatry and Neuroscience
63. Efficacy of acupuncture versus sham acupuncture on generalized anxiety disorder: a meta-analysis of randomized controlled trials
    Hongzhan Jiang, Rui Ma, Yaxin Huang, Xue-Jing Li, Yu-Fang Hao · 2025 · Frontiers in Neurology
64. Integrating physical healthcare into psychiatry for severe mental illness: A narrative review and position statement from the ECNP PAN-Health group
    René Ernst Nielsen, Heidi T. Taipale, Samuele Cortese, Elena Dragioti, Ebba Du Rietz, Joseph Firth, Paolo Fusar‐Poli, Catharina Annette Hartman, Richard I. G. Holt, Anne Høye et al. · 2026 · Neuroscience Applied
65. Should clozapine be offered as a second-line antipsychotic?
    Emma Butler, Melanie Stratford, Sameer Jauhar · 2025 · The Lancet Psychiatry
66. Antipsychotika abseits der Dopamin-D2-Blockade – Xanomelin-Trospium als Hoffnungsträger?
    Michael Paulzen, Jens Kuhn · 2025 · Der Nervenarzt
67. Feeding Two Birds with One Scone: The Case of Varenicline
    Henri‐Jean Aubin, Amandine Luquiens · 2015 · Alcoholism Clinical and Experimental Research
68. Unmet Needs in Modern Psychiatric Practice
    Gaia Sampogna, Mario Luciano, Valeria Del Vecchio, Vincenzo Giallonardo, Benedetta Pocai, Maurizio Pompili, Andrea Fiorillo · 2020 · Springer eBooks
69. Effect of necessity‐concern framework and polypharmacy on treatment adherence in psychiatric patients. Comparing an Argentinian with a Spanish sample
    Carlos De las Cuevas, Alejandro G. Villasante Tezanos, Mariano Motuca, José de León · 2021 · Human Psychopharmacology Clinical and Experimental
70. Initiating Antidepressant Medication: What is the Most Important Factor?
    Siegfried F. Kasper · 2022 · Advances in Therapy
71. Fast tracking informative clinical trials: lessons for mental health
    Stefan Michael Gold, Martin Landray, Nick Medhurst, Christian Otte · 2023 · The Lancet Psychiatry
72. Überlegungen zur Wirksamkeit von Psychopharmaka
    Stefan Leucht, Stephan Heres, John M. Davis · 2011 · Der Nervenarzt
73. Competing commitments in psychiatric research: An examination of psychiatric researchers' perspectives
    Ryan E. Lawrence, Karen Albert, Charles W. Lidz, Paul S. Appelbaum · 2012 · International Journal of Law and Psychiatry
74. Positive Psychiatry: An Introduction
    Erick Messias · 2020 · Springer eBooks
75. The Treatment of Adult ADHD: Complexity at Hand
    Stefano Pallanti, Luana Salerno · 2020 · Springer eBooks
76. The clinical significance of drug-placebo differences
    Irving Kirsch · 2017 · Epidemiology and Psychiatric Sciences
77. Irish Medical Organisation Doolin Memorial Lecture 2019: rhetoric and reality in mental health—Ireland and the world
    Brendan D. Kelly · 2019 · Irish Journal of Medical Science (1971 -)
78. The ‘rest of medicine’ and psychiatry: why paradigms would differ
    Anindya Das · 2013 · The British Journal of Psychiatry
79. Editorial: The Long-term Impact of Attention-Deficit/Hyperactivity Disorder: Lessons From the Past and Directions for the Future
    Emily A. Simonoff · 2021 · Journal of the American Academy of Child & Adolescent Psychiatry
80. Simulation investigations of thermodynamic properties for silica nanoparticles and voxelotor docking effect with hemoglobin for sickle cell disease
    Shimaa A. Jaber, Bahjat B. Kadhim, Ali Taher Mohi · 2024 · AIP conference proceedings
81. Depression, Angststörungen, bipolare Störung, Schizophrenie, Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung
    Johanna Seifert, Stefan Bleich, Roland Seifert · 2025 · Springer eBooks
82. Disorder at the Synapse: How the Active Inference Framework Unifies Competing Perspectives on Depression
    Christopher G. Davey, Paul Benjamin Badcock · 2025 · Entropy
83. Medication Efficacy: The Impact of Variability in Defining and Measuring ADHD and Executive Functioning
    Paul Beljan, Alison E. F. Reuter, Koren Ganas, Marlin Hoover · 2012 · Applied Neuropsychology Child
84. Replication and contradiction of highly cited research papers: a lesson for the Secretary of State for Health?
    Roxanne C. Keynejad, Clare Holt, Tony Rao · 2015 · BJPsych Bulletin
85. Pas si paradoxal … Neurobiologie du trouble déficit de l’attention–hyperactivité (TDAH) et mode d’action thérapeutique des psychostimulants
    Benjamin Rolland, Luc Zimmer, Hugo Prunier, Guillaume Sescousse · 2024 · Annales Médico-psychologiques revue psychiatrique
86. Medical management of ADHD in adults: part 1
    Laurence Leaver · 2025 · Drug and Therapeutics Bulletin
87. Are the effects of blood pressure lowering treatment diminishing?: meta-regression analyses
    Yoichi Sekizawa, Yoko Konishi, Moriyo Kimura · 2018 · Clinical Hypertension
88. Treatment of Schizophrenia in the 21st Century: Towards a more Personalised Approach
    Robert Hunter · 2012 · InTech eBooks
89. Understanding the Antidepressant Debate in the Treatment of Major Depressive Disorder
    Florian Naudet, Rémy Boussageon, Clément Palpacuer, Laurent Gallet, Jean‐Michel Reymann, Bruno Falissard · 2015 · Therapies
90. Psychiatry is essential for now but might eventually disappear (although this is unlikely to happen any time soon)
    Brendan D. Kelly · 2021 · Australasian Psychiatry
91. role of the gut microbiota in pathogenesis and treatment of depression
    Klaudia Bogusz, Natalia Baran, Marcela Maksymowicz, Adriana BIELAK, Aleksandra NOWAK, Łucja CYWKA, Weronika Szwed, Alicja Nowak, Piotr Artur Machowiec · 2023 · Journal of Education Health and Sport
92. Case-based learning: safe withdrawal and tapering of antidepressants
    2023 · Pharmaceutical journal/The pharmaceutical journal
93. Psychiatry and Psychotherapy: A Troubled Relationship
    Andreea Enache-Tonoiu · 2013 · Europe’s Journal of Psychology
94. The effect of baseline antipsychotic status on the 12‐month outcome in initially stabilized patients with schizophrenia
    Konstantinos Ν. Fountoulakis, Panagiotis Panagiotidis, Ioannis Nimatoudis · 2019 · Human Psychopharmacology Clinical and Experimental
95. Qualitätsgesicherte Psychiatrie und Entstigmatisierung
    Wolfgang Gäebel, Johannes Stricker · 2020 · Der Nervenarzt
96. Medication management of antipsychotic treatment in schizophrenia—A narrative review
    Matti K. Isohanni, Erika Jääskeläinen, Brian J. Miller, Anja Hulkko, Jari Tiihonen, Hans‐Jürgen Möller, Sirpa A. Hartikainen, Sanna Huhtaniska, Johannes Lieslehto · 2020 · Human Psychopharmacology Clinical and Experimental
97. Complementary and Alternative Medicine: Not Many Compliments but Lots of Alternatives
    BENNETT L. LEVENTHAL · 2013 · Journal of Child and Adolescent Psychopharmacology
98. Future Directions
    Walter Matthys, John E. Lochman · 2017
99. A magyar pszichiáter identitása. Egy tudományos felmérés tapasztalatai
    Adrienne Incze, Szabolcs Kéri, György Szekeres · 2018 · Orvosi Hetilap
100. The Maximin/Leximin Theory
     Torbjörn Tännsjö · 2019